Skip to main content

Table 1 Baseline and 6-month characteristics of treatment groups (Me [IQR])

From: Influence of adjunctive azithromycin on microbiological and clinical outcomes in periodontitis patients: 6-month results of randomized controlled clinical trial

  Baseline characteristics 6-month characteristics
Control group Test group p Control group Test group p
Teeth with DS (n) 18.0 (16.3–21.3) 14.0 (12.3–22.3) 0.412 4.0a (1.0–10.0) 4.0a (0.0–7.0) 0.616
DS (n) 47.0 (28.0–63.8) 34.0 (23.3–62.3) 0.397 5.0a (1.0–22.3) 4.0a (0.0–11.0) 0.497
DS on molars (n) 15.0 (10.3–23.0) 18.0 (11.3–23.5) 0.661 1.0a (0.3–6.8) 2.0a (0.0–6.5) 0.801
PlI (%) 40.0 (20.0–50.0) 30.0 (20.0–50.0) 0.726 10.0a (2.0–20.0) 10.0a (4.0–10.0) 0.988
PD (mm) 4.1 (3.6–4.5) 3.9 (3.7–4.5) 0.838 2.9a (2.4–3.6) 2.7a (2.4–3.1) 0.484
REC (mm) 0.4 (0.3–0.6) 0.4 (0.2–0.7) 0.895 0.7a (0.5–1.1) 0.6a (0.5–1.0) 0.661
CAL (mm) 4.2 (3.6–4.9) 4.2 (3.7–4.8) 0.988 3.3a (2.6–4.3) 3.3a (2.7–3.7) 0.770
BOP (%) 80.0 (60.0–90.0) 70.0 (50.0–90.0) 0.620 20.0a (10.0–40.0) 20.0a (10.0–20.0) 0.651
  1. Me median value, IQR interquartile range, DS diseased sites (PD ≥ 5 mm + BOP); PlI plaque index; PD probing depth; REC recession; CAL clinical attachment loss; BOP bleeding on probing; a, statistically significant change in comparison to baseline